L. Rebaud

Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study

I. Buvat, F. Merli, A. Ciarrocchi, 2022, Hematological Oncology.

18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients

I. Buvat, L. Vercellino, O. Casasnovas, 2022, The Journal of Nuclear Medicine.

DeepOS: pan-cancer prognosis estimation from RNA-sequencing data

S. Christodoulidis, H. Vanacker, D. Morel, 2021, medRxiv.

Simplicity Is All You Need: Out-of-the-Box nnUNet Followed by Binary-Weighted Radiomic Model for Segmentation and Outcome Prediction in Head and Neck PET/CT

I. Buvat, L. Rebaud, K. Girum, 2022, HECKTOR@MICCAI.

Metabolic tumor volume predicts outcome in advanced stage follicular lymphoma patients from the Relevance trial.

I. Flinn, F. Morschhauser, O. Casasnovas, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study

I. Buvat, F. Merli, A. Ciarrocchi, 2022, Hematological oncology.

Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial

L. Vercellino, O. Casasnovas, F. Morschhauser, 2023, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.